The PD-1 checkpoint inhibitor Opdivo (nivolumab) has been approved by the FDA as an initial treatment for advanced gastric cancer, adding to its approvals as a treatment for melanoma and a number of other cancers.
A new sweat sensor can detect seven inflammatory proteins seen at high levels in patients experiencing the kind of extreme immune reaction seen in COVID-19 and in some flu patients, which researchers hope will speed up treatment.
The researchers used mRNA technology to code for Cas13a, which destroys parts of the RNA genetic code that viruses use to replicate in cells in the lungs. Using a guide strand, researchers can provide a map that basically tells the Cas13a protein where to attach to the viruses’ RNA and begin to destroy it.
Researchers at the Baylor College of Medicine report that they have found that microbes in the gut may contribute to certain symptoms associated with complex neurological disorders, which also suggests that microbe-inspired therapies may one day help to treat them.
Known as Explainable Multi-Omics Graph Integration (EMOGI), the machine learning method predicted 165 new cancer genes by combining multiomics pan-cancer data—such as mutations, copy number changes, DNA methylation and gene expression—together with protein–protein interaction (PPI) networks.
The researchers found that mutations in KMT2C and KMT2D make non-small cell lung cancer more sensitive to Poly (ADP-ribose) polymerase (PARP) inhibitors, which are already approved for treating prostate, pancreatic, ovarian, and breast cancer patients.
A team of researchers from Centre de Recherche en Cancerologie de Marseille (CRCM), INSERM in France have developed a new method for capturing the metabolic signature of pancreatic ductal adenocarcinoma to predict clinical outcomes.
The ABCC1 protein has the ability to break down amyloid plaques in Alzheimer’s disease and researchers show in a new study that increasing expression of this gene may even prevent the neurodegenerative disease from developing in the first place.
Around 3.5% of cancer patients treated with immune checkpoint inhibitors have side effects bad enough to require hospitalization. A new study shows that factors such as being given a combination of different immune checkpoint inhibitors, having lung cancer, and younger age all increase this risk.
The new automation friendly reagents allow laboratories testing for COVID-19 have a tool that allows them to skip the RNA extraction step of the many testing workflows and move directly to PCR amplification.
With the aid of the n-lorem Foundation, doctors and patients now have hope of finding treatments to the most rare of genetic diseases.
A wider reach—in patients and data—promises better outcomes.
Broader, more diverse genomic data sets allow better training of polygenic risk score algorithms, moving them from research models into the clinic.
This year we highlight a range of leaders in precision medicine ranging from infectious disease experts to CRISPR researchers to company founders.